Related Experiment Video

Updated: Jul 11, 2026

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical

Kerrington D Smith1, Michael Y Shao, Mitchell C Posner

  • 1MD Anderson Cancer Center, Department of Surgical Oncology, 1515 Holcombe Blvd. Unit 444, Houston TX 77030, USA. kdsmith@mdanderson.org

Future Oncology (London, England)
|October 12, 2007
PubMed

Insights

Oncolytic Herpes simplex virus-1 (HSV-1) mutants show promise for cancer therapy. These engineered viruses selectively destroy tumor cells overexpressing MEK, offering a targeted approach to oncolysis.

Area of Science:

  • Virology
  • Oncology
  • Gene Therapy

Background:

  • Oncolytic Herpes simplex virus-1 (HSV-1) mutants, specifically those with the gamma134.5 gene deleted (Deltagamma134.5), are being developed as cancer therapies.
  • The efficacy of these mutants is tumor cell-type specific and attenuated in normal tissues due to the activation of the protein kinase R (PKR)-mediated host defense pathway, which inhibits protein synthesis.

Purpose of the Study:

  • To investigate the potential of Deltagamma134.5 mutants for selective tumor cell destruction.
  • To explore the role of MAPK kinase (MEK) overexpression in supporting robust mutant replication and tumor oncolysis.
  • To assess the feasibility of systemic delivery for targeting metastases and overcoming barriers to HSV-1 oncolytic therapy.

Main Methods:

  • Utilized Deltagamma134.5 HSV-1 mutants engineered for cancer therapy.
  • Investigated tumor cell-type specificity and attenuation in normal tissues.
  • Examined the mechanism of MEK-mediated inhibition of PKR to enable viral replication.

Main Results:

  • Deltagamma134.5 mutant replication and cytolysis are specific to tumor cell type and attenuated in normal tissues.
  • Tumor cells overexpressing MEK support robust replication of Deltagamma134.5 mutants by inhibiting PKR.
  • Systemic delivery of these mutants shows potential for targeting and destroying metastases from various solid human tumors overexpressing MEK.

Conclusions:

  • Deltagamma134.5 HSV-1 mutants offer a promising strategy for oncolytic therapy, particularly in tumors with MEK overexpression.
  • Overcoming barriers such as innate and adaptive immunity, and hepatic adsorption, is crucial for successful systemic delivery.
  • Future patient selection for Deltagamma134.5 oncolytic therapy may be guided by biopsy-determined tumor MEK status.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Related Concept Videos

Herpes01:28

Herpes

Herpes simplex type 1 (HSV‑1) is a widespread pathogen responsible for orolabial lesions. It is an enveloped, double-stranded DNA (dsDNA) virus belonging to the family Herpesviridae. Once the virus infects a host cell, its double‑stranded DNA genome is delivered into the nucleus, where a coordinated cascade of immediate‑early, early, and late gene expression directs viral DNA replication, structural protein synthesis, and virion assembly. After primary infection of epithelial cells, HSV-1...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Genital Herpes01:23

Genital Herpes

Genital herpes is a sexually transmitted infection primarily caused by herpes simplex virus type 2 (HSV-2), though herpes simplex virus type 1 (HSV-1) is increasingly implicated in genital infections, particularly among younger populations. Transmission occurs mainly through sexual contact, with asymptomatic viral shedding serving as a major route of spread. This characteristic makes HSV-2 difficult to control at a population level, as individuals may unknowingly transmit the virus even in the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...